Coherus Oncology (CHRS) Study result summary

Study overview

• Interim TREGCHECK data covered more than 120 patients across esophageal, upper GI, colorectal and head and neck cancers; tagmokitug was generally combined with toripalimab.

• Activity was observed across tumor types, with dose-related signals in GI cohorts and enrichment in HPV-positive head and neck cancer.

First-line ESCC

• The 700 mg tagmokitug + toripalimab + chemotherapy cohort had 10 safety-evaluable and 8 efficacy-evaluable patients at cutoff; all evaluable patients had tumor shrinkage.

• Confirmed ORR at the Oct. 14 cutoff was 75% (6/8) overall and 100% in PD-L1-positive patients, including 1 confirmed complete response.

• Two additional partial responses were confirmed after cutoff, raising cORR to 89% (8/9).

• CBR was ~87%; 4 of 8 evaluable patients remained on treatment at cutoff, with activity reported near 8 months; PFS follow-up was immature.

• Enrollment continued, with expansion to 30–40 patients planned; first-line expansion was discussed for Q2–Q3 2027, pending durability data and FDA discussions.

Second-line ESCC

• The cohort randomized patients to 300 mg or 700 mg tagmokitug plus toripalimab; 17 were safety-evaluable and 8 efficacy-evaluable at cutoff.

• At 700 mg, interim cORR was 16.7% (1/6) and CBR was 33.3% (2/6); one additional partial response was unconfirmed, and activity included PD-L1-negative disease.

• A dose-response signal favored 700 mg; median PFS was 5.5 months versus a cited U.S. standard-of-care benchmark of 3.4 months, with follow-up still maturing.

• Durable stable disease included a PD-L1-negative patient beyond 33 weeks; six patients remained on treatment across the cohort, including two at 700 mg near 8 months.